)
Visual
test
MAIA Biotechnology
MAIA Biotechnology (MAIA) investor relations material
MAIA Biotechnology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Mar, 2026
Executive summary
Clinical-stage biopharma focused on telomere-targeting immunotherapies for cancer, with lead asset ateganosine (THIO) in advanced clinical development for NSCLC and other solid tumors.
Significant clinical milestones in 2025: expansion of THIO-101 Phase 2 trial, initiation of THIO-104 Phase 3 pivotal trial, and multiple global collaborations.
Fast Track designation granted by FDA for ateganosine in NSCLC; Orphan Drug and Rare Pediatric Disease designations for other indications.
Financial highlights
Net loss for 2025 was $22.4M, compared to $23.3M in 2024.
Research and development expenses increased 45% to $14.5M; general and administrative expenses rose 40% to $9.7M.
Cash at year-end 2025 was $8.7M, with working capital of $3.9M and total assets of $9.7M.
Other income (expense), net, improved to $1.9M income from a $6.3M expense in 2024, mainly due to warrant liability revaluation.
Outlook and guidance
Sufficient liquidity for at least 12 months post-report due to $33M raised in early 2026 public offering.
Plans to seek accelerated approval for ateganosine in NSCLC in 2026, with additional Phase 2 and 3 trials in other tumor types planned.
Ongoing expansion of clinical pipeline and pursuit of additional strategic collaborations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MAIA Biotechnology
- THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIA
Biotech Showcase 2025 Investor Conference10 Jan 2026 - Key votes include director elections, auditor ratification, and a major share authorization increase.MAIAProxy Filing2 Dec 2025
- Shareholders will vote on director elections, auditor ratification, and doubling authorized shares.MAIAProxy Filing2 Dec 2025
- Shareholders to vote on director elections, auditor ratification, and doubling authorized common stock.MAIAProxy Filing2 Dec 2025
- Q3 2025 saw higher losses, key clinical progress, and a shift toward digital asset treasury.MAIAQ3 20257 Nov 2025
- Net loss improved 40% year-over-year in Q2 2025, but ongoing capital needs persist.MAIAQ2 202511 Aug 2025
- Q3 net loss narrowed to $2.74M; cash rose to $8.69M; further funding needed for operations.MAIAQ3 202413 Jun 2025
- Q2 net loss widened to $8.9M as warrant revaluations offset lower operating expenses.MAIAQ2 202413 Jun 2025
- THIO shows strong Phase 2 efficacy, but MAIA faces ongoing losses and urgent funding needs.MAIAQ4 20249 Jun 2025
Next MAIA Biotechnology earnings date
Q1 20268 May, 2026
MAIA Biotechnology
Next MAIA Biotechnology earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage